Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

7,146JPY
2:01am GMT
Change (% chg)

¥55 (+0.78%)
Prev Close
¥7,091
Open
¥7,142
Day's High
¥7,177
Day's Low
¥7,081
Volume
394,000
Avg. Vol
1,412,899
52-wk High
¥7,796
52-wk Low
¥5,200

Select another date:

Mon, Oct 29 2018

Shionogi aims to double flu-drug market with FDA-approved treatment

TOKYO Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

Shionogi aims to double flu-drug market with FDA-approved treatment

TOKYO, Oct 29 Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

FDA approves first new flu drug in almost two decades

Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

CORRECTED-FDA approves first new flu drug in almost two decades

Oct 24 Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

FDA approves blood disorder drug made by Japan's Shionogi

The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

U.S. FDA approves blood disorder drug made by Japan's Shionogi

July 31 The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

Select another date: